Reaction
Endometrial Cancer reporting signals
As of the last recalculation, Endometrial Cancer appears in 2,177 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is RALOXIFENE HYDROCHLORIDE (PRR 64.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Raloxifene Hydrochloride | 94 | 64.3 | 64.7 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 60 | 25.0 | 25.0 |
| Medroxyprogesterone Acetate | 81 | 16.1 | 16.1 |
| Conjugated Estrogens | 89 | 15.2 | 15.2 |
| Estrogens, Conjugated | 89 | 14.9 | 14.9 |
| Testosterone | 27 | 11.2 | 11.2 |
| Zinc | 27 | 10.6 | 10.6 |
| Zinc Chloride | 27 | 10.5 | 10.5 |
| Zinc Gluconate | 27 | 10.0 | 10.0 |
| Zonisamide | 13 | 8.4 | 8.5 |
| Estradiol | 74 | 8.4 | 8.4 |
| Progesterone | 20 | 8.4 | 8.4 |
| Atovaquone | 6 | 7.1 | 7.1 |
| Bupivacaine | 5 | 5.1 | 5.1 |
| Carboplatin | 58 | 4.5 | 4.5 |
| Selinexor | 4 | 4.4 | 4.4 |
| Tofacitinib Citrate | 6 | 4.4 | 4.4 |
| Testosterone Cypionate | 4 | 4.3 | 4.3 |
| Paclitaxel (Aibumin-Bound) | 36 | 4.2 | 4.2 |
| Levonorgestrel | 85 | 4.2 | 4.2 |
| Lenvatinib | 14 | 4.1 | 4.1 |
| Ranitidine | 79 | 3.9 | 3.9 |
| Paclitaxel | 39 | 3.8 | 3.8 |
| Inclisiran | 3 | 3.6 | 3.6 |
| Ranitidine Hydrochloride | 20 | 3.5 | 3.5 |
| Interferon Beta-1A | 65 | 3.3 | 3.3 |
| Guselkumab | 12 | 3.2 | 3.2 |
| Risankizumab-Rzaa | 25 | 2.9 | 2.9 |
| Olaparib | 6 | 2.7 | 2.7 |
| Peginterferon Beta-1A | 3 | 2.2 | 2.2 |
| Onabotulinumtoxina | 17 | 2.1 | 2.1 |
| Ixekizumab | 7 | 1.8 | 1.8 |
| Copper | 4 | 0.9 | 0.9 |